CARLSBAD, California, January 27, 2025 — ALZpath, Inc., a leading developer of diagnostic tools and solutions for Alzheimer’s disease and related dementias, today announced the board’s appointment of Mike Banville as CEO, effective January 1. Banville replaces Chad Holland, who served in a fractional role as CEO while ALZpath transitioned toward its next stage of development.
Banville joins an experienced leadership team, a board of directors with deep industry knowledge, relationships and expertise, and a scientific advisory board composed of the leading researchers in Alzheimer’s disease and blood-based biomarkers.
“Mike has a strong leadership background and excellent track record in driving business growth across companies large and small, with specialized experience scaling early-stage companies,” said Jerre Stead, ALZpath co-founder and board chair. “He is well positioned to lead ALZpath in its next phase of growth and is committed to advancing ALZpath’s culture as a collaborative partner to the research, academic, biotech, and clinical communities.”
Banville has led organizations through a wide range of business stages across sectors including healthcare, higher education, technology and energy. He previously served as CEO at Game Plan, Sensable Health and SSB, and held executive roles at IHS Markit, including business unit and commercial leadership and global sales strategies.
“I am excited to take on this role with a company that is transforming Alzheimer’s diagnosis at a pivotal time when new treatments are available, and preventions are on the horizon,” said Banville. “ALZpath’s enablement of accessible, early, and accurate diagnosis will change the lives of patients, their families, and communities globally and I am grateful to take part in its mission.”
Founded in 2020, ALZpath is transforming Alzheimer’s diagnosis and treatment monitoring. By 2050, nearly 140 million people will be living with dementia, and as new treatments and preventions enter the market, the urgency for early and accurate diagnosis rises. Blood-based assays, utilizing the ALZpath pTau217 antibody, have demonstrated similar diagnostic accuracy as traditional methods, such as PET imaging and cerebral spinal fluid (CSF) testing, but with the accessibility and affordability of a simple, less invasive blood test that can be administered in a variety of clinical settings.
ALZpath’s proprietary antibody is utilized under license agreements as a component of blood-based assays designed for both clinical and research purposes, including on widely used platforms developed by Roche, Beckman Coulter, Neurocode, Alamar and BioTechne among others. The ALZpath pTau217 antibody was named by TIME Magazine as one of the best inventions in medical care in 2024.